Mark F. Kubik has served as Chief Business Officer of Velocity Sciences since February 2017. Mark’s scientific background and business development leadership spans over 25 years in roles of increasing impact in bioscience and drug discovery and development. As a researcher, Mr. Kubik performed important proof of concept experiments for early generation in vitro evolution technologies, precursors to some of Velocity’s current leading discovery technologies. As a business development executive, Mr. Kubik has led negotiation of transformative and award-winning technology and product partnerships for leading therapeutics companies, focused in the antibody and empowered antibody arena. Among others, these include global co-development agreements a) on behalf of Abgenix with Immunex (now Amgen) on Vectibix® (panitumumab), b) on behalf of Seattle Genetics with Takeda on Adcetris® (brentuximab vedotin) and c) on behalf of MacroGenics with Gilead, a collaboration which was awarded Alliance of the Year in Life Sciences by the LES (Licensing Executives Society), and was instrumental in MacroGenics transition from private to a public company. Mark graduated cum laude from the University of Colorado-Boulder (CU) in Molecular, Cellular and Developmental Biology (MCDB) and also holds an MBA in Finance from CU.